RxDoctor Payments Data

James Neahring, MD

Cardiovascular Disease · Newburgh, INNPI 1104874379

Payments from drug & device makers

$40,918in general payments, 2019–2025

Across 96 payments — averaging $426.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$19K
  • Novartis$12K
  • Pfizer$7K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Abbott$48
  • Boehringer Ingelheim$33

What the payments were for

  • Speaking & faculty fees$39,04895%
  • Travel & lodging$6272%
  • Food & beverage$1,2153%
  • Education$280%

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca38$19,408
Novartis30$12,278
Pfizer19$7,153
E.r. Squibb & Sons, L.L.C.5$1,998
Abbott2$48
Boehringer Ingelheim2$33

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,918 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$394,904
Medicare patients
3,646
Services billed
6,697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban725$862,062
EntrestoSacubitril/Valsartan269$359,345
XareltoRivaroxaban153$177,169
FarxigaDapagliflozin Propanediol105$120,422
Repatha SureclickEvolocumab89$104,740
BrilintaTicagrelor39$31,315
JardianceEmpagliflozin13$23,066
Praluent PenAlirocumab22$20,558
Metoprolol Succinate1,087$13,210
Ranolazine ErRanolazine79$10,251
Ezetimibe217$5,763
Potassium Chloride314$5,301
Diltiazem 24hr Er (Cd)Diltiazem Hcl201$4,595
Atorvastatin Calcium710$4,591
Isosorbide Mononitrate ErIsosorbide Mononitrate508$4,082

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$7,153$862,062725 claims
NovartisEntresto$12,278$359,345269 claims
AstraZenecaFarxiga, Brilinta$19,408$151,737144 claims
Boehringer IngelheimJardiance$33$23,06613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Newburgh

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →